ArticleFrontiers in oncology2025
Emodin inhibits colon cancer tumor growth by suppressing tumor cell glycolysis through inhibition of NAT10-mediated PGK1 ac4C modification.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The functions, mechanisms and clinical relevance of RNA and protein acetyltransferase NAT10: a comprehensive review.Cell biology and toxicology · 2026Review
- NAT10 as a central node in cancer biology: integrating epitranscriptomic regulation, metabolic reprogramming, and immune modulation.Frontiers in immunology · 2026Review
- Advances in protein dot blot: principles, technical specifics, applications, and future perspectives.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inhibition of glycolysis represents a potent therapeutic approach for colon cancer. Emodin, a natural plant-derived compound with anticancer properties, has shown efficacy in cancer treatment. NAT10 promotes cancer progression by catalyzing ac4C production on mRNAs, but it remains unclear whether emodin regulates glycolysis in colon cancer cells by targeting NAT10. This study aimed to investigate the role of emodin in glycolysis regulation in colon cancer and its underlying mechanisms. Methods: Glycolysis was assessed by measuring cell proliferation, glucose uptake, lactate production, and extracellular acidification rate. The ac4C levels and NAT10 expression were measured by dot blot and quantitative real-time PCR. The underlying mechanism was investigated by methylated RNA immunoprecipitation (MeRIP), RIP and dual luciferase reports. The effect of emodin on tumor growth in vivo was evaluated by hematoxylin and eosin staining and immunohistochemistry staining. Results: Results showed that emodin inhibited glycolysis in colon cancer cells in a dose-dependent manner, and suppressed the ac4C levels and NAT10 expression of cells. Moreover, NAT10 overexpression restored glycolysis in colon cancer cells inhibited by emodin. Mechanistically, NAT10 promotes glycolysis of colon cancer cells by stabilizing PGK1 expression through enhancing ac4C modification on PGK1. In vivo experiments suggested that emodin inhibited colon cancer tumor growth, as well as NAT10 and PGK1 expression. Discussion: In conclusion, we demonstrated that emodin inhibited tumor growth of colon cancer by suppressing glycolysis in tumor cells through inhibiting NAT10-mediated ac4C modification of PGK1, indicating that emodin is an effective medicine for treatment of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.